Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 3/20 | 0.48 |
| ▸ | NTRK2 | Q16620 | 4/20 | 0.44 |
| ▸ | CSNK2A2 | P19784 | 3/20 | 0.38 |
| ▸ | CSNK2A1 | P68400 | 3/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 4/20 | 0.38 |
| ▸ | TNK2 | Q07912 | 8/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12537481 | 0.83 | NTRK1 (0.51) | NTRK1NTRK2CSNK2A2CSNK2A1PIK3CD | |
| SCHEMBL13869077 | 0.83 | NTRK1 (0.44) | NTRK1NTRK2CSNK2A2CSNK2A1PIK3CD | |
| SCHEMBL21199390 | 0.73 | CSNK2A2 (0.40) | NTRK1NTRK2CSNK2A2CSNK2A1PIK3CD | |
| SCHEMBL12537733 | 0.72 | NTRK1 (0.53) | NTRK1NTRK2CSNK2A2CSNK2A1TNK2 | |
| SCHEMBL14651915 | 0.71 | NTRK1 (0.38) | NTRK1NTRK2CSNK2A2CSNK2A1PIK3CD | |
| SCHEMBL19279707 | 0.71 | CSNK2A2 (0.39) | NTRK1CSNK2A2CSNK2A1PIK3CD | |
| SCHEMBL3688565 | 0.71 | L3MBTL1 (0.47) | — | |
| SCHEMBL28508014 | 0.70 | NTRK1 (0.38) | NTRK1NTRK2CSNK2A2CSNK2A1PIK3CD | |
| SCHEMBL1925784 | 0.70 | NTRK2 (0.78) | NTRK1NTRK2 | |
| SCHEMBL12537596 | 0.70 | NTRK1 (0.41) | NTRK1NTRK2CSNK2A2CSNK2A1PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7514435-B2 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-04-07 | — | — | US | disclosed |
| US-20070149534-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149534-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | NTRK2, NTRK3, NTRK1 | NTRK1 3/4885NTRK2 1/4885CSNK2A2 621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.